Anika Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-10 pm EDT			5-day change	1st Jan Change
14.46 ^USD	-3.34%		+0.42%	+50.47%

Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT

Published on 11/05/2025 at 01:20 pm EST - Modified on 12/02/2025 at 08:53 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, ladies and gentlemen, and welcome to Anika's third quarter earnings conference call. [Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT
Feb. 26	Anika Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Anika Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026	CI
Jan. 08	Anika Therapeutics Appoints CFO Stephen Griffin as Chief Executive Officer	MT
Jan. 08	Anika Therapeutics, Inc. Announces Executive Changes	CI
Jan. 08	Anika Therapeutics, Inc. Announces Chief Executive Officer Changes	CI
Nov. 05	Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024.	CI
Nov. 05	Anika Therapeutics, Inc., Q3 2025 Earnings Call, Nov 05, 2025
Nov. 05	Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 05	Anika beats Q3 revenue estimates, maintains guidance	RE
Nov. 05	Anika Therapeutics, Inc. Confirms Earnings Guidance for the Full Year 2025	CI
Nov. 05	Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast Cartilage Repair Scaffold and Data from U.S. Pivotal Fasttrack Phase III Study	CI
25-07-30	Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024.	CI